GB0916335D0 - Medicaments - Google Patents

Medicaments

Info

Publication number
GB0916335D0
GB0916335D0 GBGB0916335.3A GB0916335A GB0916335D0 GB 0916335 D0 GB0916335 D0 GB 0916335D0 GB 0916335 A GB0916335 A GB 0916335A GB 0916335 D0 GB0916335 D0 GB 0916335D0
Authority
GB
United Kingdom
Prior art keywords
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0916335.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Martin W J
Original Assignee
Martin W J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martin W J filed Critical Martin W J
Priority to GBGB0916335.3A priority Critical patent/GB0916335D0/en
Publication of GB0916335D0 publication Critical patent/GB0916335D0/en
Priority to PCT/GB2010/051561 priority patent/WO2011033310A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0916335.3A 2009-09-17 2009-09-17 Medicaments Ceased GB0916335D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0916335.3A GB0916335D0 (en) 2009-09-17 2009-09-17 Medicaments
PCT/GB2010/051561 WO2011033310A1 (en) 2009-09-17 2010-09-17 Encapsulated intestinal flora extracted from feces for use in the treatment of gastrointestinal disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0916335.3A GB0916335D0 (en) 2009-09-17 2009-09-17 Medicaments

Publications (1)

Publication Number Publication Date
GB0916335D0 true GB0916335D0 (en) 2009-10-28

Family

ID=41277879

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0916335.3A Ceased GB0916335D0 (en) 2009-09-17 2009-09-17 Medicaments

Country Status (2)

Country Link
GB (1) GB0916335D0 (en)
WO (1) WO2011033310A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2011209940B2 (en) 2010-02-01 2015-08-20 Ferring Microbiome Inc. Bacteriotherapy for clostridium difficile colitis
BR112013002667B1 (en) 2010-08-04 2020-02-04 Thomas Julius Borody intestinal flora transplantation compositions and methods for making and using them and devices for administering them
EP3135291A1 (en) 2011-03-09 2017-03-01 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2014152484A1 (en) * 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
EP2750682B1 (en) * 2011-10-11 2016-05-18 Achim Biotherapeutics AB Composition comprising anaerobically cultivated human intestinal microbiota
WO2013090825A1 (en) * 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
ES2792106T3 (en) * 2012-05-18 2020-11-10 Genome Res Ltd Methods and groups
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
CA2896795A1 (en) * 2012-11-26 2014-05-30 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
EP3904502A3 (en) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions and methods
WO2014121298A2 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Methods of populating a gastrointestinal tract
US20160040215A1 (en) * 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
JP2016519664A (en) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド Microbial composition and method based on network
US20160129053A1 (en) * 2013-05-24 2016-05-12 President And Fellows Of Harvard College Methods of isolating microorganisms and uses thereof
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
LT3003330T (en) 2013-06-05 2018-10-25 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
BR112016011830A2 (en) 2013-11-25 2017-09-26 Seres Therapeutics Inc synergistic bacterial compositions and methods for their production and use.
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
GB201421735D0 (en) * 2014-12-07 2015-01-21 Craig Nicola M Humanized gut microbiota
SE1550189A1 (en) 2015-02-19 2016-08-20 Achim Biotherapeutics Ab Therapeutic and prophylactic composition produced by microbiota
CA2985729C (en) 2015-05-11 2023-05-09 Mybiotics Pharma Ltd Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut
AU2016262615C1 (en) 2015-05-14 2021-06-10 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
PT3297644T (en) 2015-05-22 2022-03-30 Univ Arizona State METHODS TO TREAT AUTISM SPECTRUM DISORDERS AND ASSOCIATED SYMPTOMS
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102175829B1 (en) 2015-06-09 2020-11-06 리바이오틱스, 인코퍼레이티드 Microflora reconstitution treatment (MRT) composition and a method of manufacture thereof
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
RU2022101485A (en) 2016-05-25 2022-04-27 Майбиотикс Фарма Лтд. COMPOSITION AND METHODS FOR MICROBIOTA THERAPY
KR102658297B1 (en) 2016-06-14 2024-04-18 베단타 바이오사이언시즈, 인크. Treatment of clostridium difficile infection
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018140931A1 (en) * 2017-01-30 2018-08-02 The Board Of Regents Of The University Of Texas System Compositions and methods for fecal microbiota transplantation
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (en) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 Compositions and methods for treating Parkinson's Disease (PD) and related disorders
JP2020521760A (en) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー Lyophilized compositions containing fecal microbial-based therapeutic agents and methods of making and using same
JP2020530494A (en) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． Compositions and Methods for Maintaining and Restoring a Healthy Intestinal Barrier
AU2018318132B2 (en) 2017-08-14 2025-06-26 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
KR20200079292A (en) 2017-10-30 2020-07-02 세레스 테라퓨틱스, 인코포레이티드 Compositions and methods for treating antibiotic resistance
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US12161680B2 (en) * 2018-08-17 2024-12-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
CA3114423A1 (en) 2018-09-27 2020-04-02 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
KR20220049523A (en) 2019-07-19 2022-04-21 핀치 테라퓨틱스 홀딩스 엘엘씨 Methods and products for the treatment of gastrointestinal disorders
KR20220080104A (en) 2019-09-13 2022-06-14 핀치 테라퓨틱스 홀딩스 엘엘씨 Compositions and methods for treating autism spectrum disorders
JP2022552005A (en) 2019-10-18 2022-12-14 フィンチ セラピューティクス ホールディングス エルエルシー Compositions and methods for delivering bacterial metabolites to a subject
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
TW202140049A (en) 2020-01-10 2021-11-01 美商芬奇治療控股有限責任公司 Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
US20230201265A1 (en) 2020-03-31 2023-06-29 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
CN114686556A (en) * 2020-12-31 2022-07-01 石家庄市疾病预防控制中心（石家庄市卫生检测中心） A kind of detection method of intestinal flora
EP4643852A1 (en) 2024-04-29 2025-11-05 Mikrobiomik Healthcare Company S.L. Pharmaceutical composition comprising a processed faecal composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001335A1 (en) * 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
US5733568A (en) * 1993-12-03 1998-03-31 Lafor Laboratories Limited Micro-encapsulated lactobacilli for medical applications
UA59394C2 (en) * 1998-03-27 2003-09-15 Каділа Фармацевтікелс (І.Ей) Лтд. Process of preparing stable fixed dose composition of anti-infective agent with microorganisms as active ingredients
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
DK1885343T3 (en) * 2005-05-20 2012-01-16 Dow Global Technologies Llc Monitoring an Oral Drug Compliance Using Radio Frequency Identification Tags (RFID Tags)
DE102006062250A1 (en) * 2006-12-22 2008-06-26 Roland Saur-Brosch Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort
US8852917B2 (en) 2007-11-30 2014-10-07 University College Cork Thuricin CD, an antimicrobial for specifically targeting Clostridium difficile

Also Published As

Publication number Publication date
WO2011033310A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
GB0916335D0 (en) Medicaments
DK2457337T3 (en) Specialtilpasset impuls-burst
DK2442650T4 (en) Sublingualt apomorfin
IL217969A (en) Inhaler
GB2467388A8 (en) Inhaler
ZA201108257B (en) Inhaler
AU331057S (en) Inhaler
EP2462514A4 (en) Greenbooks
IL216700A0 (en) Inhaler
GB0915319D0 (en) Combination medicament
GB0914738D0 (en) Inhalers
GB0916332D0 (en) Medicaments
GB0922519D0 (en) Inhaler
EP2510125A4 (en) Hyperprimers
GB0901902D0 (en) Medicament
GB0903318D0 (en) Medicament
AU4924P (en) Bonscablue Scaevola aemula
AU4925P (en) Bonscawi Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
AU4926P (en) Bonscalib Scaevola aemula
GB0910772D0 (en) Pharmaceutical
GB201019774D0 (en) Medicaments
GB0903360D0 (en) Concept seven
GB0903335D0 (en) Concept three
GB201206482D0 (en) #magnotherapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)